Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors-Reference-Cited by-同舟云学术

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors

Published:2023-12-04 Issue:1 Volume:15 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Yoshimoto Sho¹,Chester Nicholas²,Xiong Ailian¹,Radaelli Enrico³,Wang Hong²,Brillantes Marc²,Gulendran Gayathri⁴,Glassman Patrick⁵,Siegel Don L.⁴⁶,Mason Nicola J.¹³⁴^ORCID

Affiliation:

1. Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA

2. Vetigenics LLC, B-Labs, Cira Center, Philadelphia, PA, USA

3. Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA

4. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

5. Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA

6. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Funder

V Foundation

Japan Society for the Promotion of Science

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2023.2287250

Reference41 articles.

1. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

2. Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

3. Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

4. Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade

5. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of a PD-1/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous B cell lymphoma;iScience;2024-09

2. Comprehensive Analysis of Microsatellite Instability in Canine Cancers: Implications for Comparative Oncology and Personalized Veterinary Medicine;Animals;2024-08-27

3. Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs;Veterinary Immunology and Immunopathology;2024-08

4. Molecular and Pathobiology of Canine Mammary Tumour: Defining a Translational Model for Human Breast Cancer;Veterinary and Comparative Oncology;2024-07-16

5. Immunotherapy with genetically engineered T cells holds promise for the treatment of nonmalignant diseases in the dog;Journal of the American Veterinary Medical Association;2024-04-16